Cardiff Oncology: Mark Erlander, CEO
Clinical-stage oncology therapeutics company Cardiff Oncology (recently renamed from Trovagene) has named Mark Erlander to the position of CEO. He will transition from his role as chairman of the company.
Erlander, who had served as chief scientific officer since joining the firm in 2013, said, “I'm excited to lead our company into the next stage of development that includes continuing to rapidly advance development of our investigational drug, onvansertib, in cancers with the greatest medical need for new effective treatments."